Cardiol Net Interest Income from 2010 to 2026
| CRDL Stock | USD 1.06 0.07 7.07% |
Net Interest Income | First Reported 2020-06-30 | Previous Quarter 180.7 K | Current Value 122.3 K | Quarterly Volatility 200.4 K |
Check Cardiol Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiol Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.4 M, Interest Income of 707.2 K or Depreciation And Amortization of 155 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0 or PTB Ratio of 8.31. Cardiol financial statements analysis is a perfect complement when working with Cardiol Therapeutics Valuation or Volatility modules.
Cardiol | Net Interest Income | Build AI portfolio with Cardiol Stock |
Historical Net Interest Income data for Cardiol Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Cardiol Therapeutics Class represents a compelling investment opportunity.
Latest Cardiol Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Cardiol Therapeutics Class over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Cardiol Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiol Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Cardiol Net Interest Income Regression Statistics
| Arithmetic Mean | 402,991 | |
| Coefficient Of Variation | 189.17 | |
| Mean Deviation | 635,780 | |
| Median | (54,444) | |
| Standard Deviation | 762,351 | |
| Sample Variance | 581.2B | |
| Range | 2.7M | |
| R-Value | 0.76 | |
| Mean Square Error | 262.1B | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | 114,693 | |
| Total Sum of Squares | 9.3T |
Cardiol Net Interest Income History
About Cardiol Therapeutics Financial Statements
Cardiol Therapeutics investors utilize fundamental indicators, such as Net Interest Income, to predict how Cardiol Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 1.4 M | 1.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Cardiol Therapeutics Correlation against competitors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. Projected growth potential of Cardiol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cardiol Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cardiol Therapeutics requires distinguishing between market price and book value, where the latter reflects Cardiol's accounting equity. The concept of intrinsic value - what Cardiol Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cardiol Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Cardiol Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiol Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiol Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.